A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3

Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report

(2014) Angelika Bezan et al.   BMC CANCER

Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study

(2014) Klaus Pietzner et al.   MEDICAL ONCOLOGY

Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma - a Report of 2 Cases

(2014) Thomas Thomaidis et al.   Oncology Research and Treatment

Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer

(2012) Fausto Petrelli et al.   Targeted Oncology

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

(2010) Peter Ruf et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

(2010) Diane Seimetz et al.   CANCER TREATMENT REVIEWS

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Monoclonal antibody-induced cytokine-release syndrome

(2009) Peter J Bugelski et al.   Expert Review of Clinical Immunology

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute